Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 147
Filter
1.
Arch Dermatol Res ; 316(5): 149, 2024 May 09.
Article in English | MEDLINE | ID: mdl-38724802

ABSTRACT

Xanthelasma palpebrarum (XP) is the predominant form of cutaneous xanthoma, as it accounts for greater than 95% of cases. It is characterized by the presence of foam cell clusters containing a large amount of low-density lipoprotein (LDL), which are located in the connective tissue of skin, tendons, and fascia. XP lesions commonly present as distinctive yellow-orange macules, papules, or nodules, and are primarily on the upper eyelids as well as the inner canthus. Women are affected twice as often as men, with lesions typically emerging between the ages of 35 and 55. The pathophysiology of XP involves abnormal lipid metabolism and is often associated with hyperlipidemic states like Type II and IV hyperlipidemia, hypothyroidism, weight gain, and fatty diet. Despite the availability of various treatment methods, current XP management lacks standardization, particularly due to limited comparative research. To address this gap, we conducted an extensive literature review of 45 studies published between 2012 to 2023, which provides an updated overview of current XP treatment modalities. This comprehensive analysis will inform researchers and clinicians on the evolving landscape of XP management.


Subject(s)
Eyelid Diseases , Xanthomatosis , Humans , Xanthomatosis/therapy , Xanthomatosis/diagnosis , Eyelid Diseases/therapy , Eyelid Diseases/diagnosis , Eyelid Diseases/metabolism , Female , Eyelids/pathology , Male , Adult
2.
Clin Dermatol ; 42(4): 343-350, 2024.
Article in English | MEDLINE | ID: mdl-38281689

ABSTRACT

Benign tumors of the eye and eyelid are common in children and adults, and they rarely undergo malignant transformation. Their workup and management have evolved over the years with increasing advancements in surgical and laser therapies. This contribution focuses on describing the following benign eye and eyelid tumors and their diagnostic and treatment approaches: congenital and acquired melanocytic nevi; nevus of Ota (Hori nevus); conjunctival papilloma; seborrheic keratosis; epidermoid cyst; dermoid cyst; milium; xanthelasma; hemangioma (cherry angioma and pyogenic granuloma); neurofibroma; neurilemmoma (schwannoma); and fibroepithelial polyp. Surgical removal is the primary treatment approach for many of these benign tumors. With advancements in laser technologies, there are now several laser types that can be used in the treatment of these benign eye and eyelid tumors. Other treatment modalities include cryosurgery, electrosurgery, and topical or intralesional medications. We hope this review will provide a reference to dermatologists and ophthalmologists in their approach to evaluation and management of benign eye and eyelid tumors.


Subject(s)
Eyelid Neoplasms , Humans , Eyelid Neoplasms/therapy , Eye Neoplasms/therapy , Eye Neoplasms/diagnosis , Dermoid Cyst/therapy , Neurofibroma/therapy , Neurofibroma/surgery , Hemangioma/therapy , Epidermal Cyst/therapy , Epidermal Cyst/diagnosis , Epidermal Cyst/surgery , Nevus, Pigmented/therapy , Keratosis, Seborrheic/therapy , Keratosis, Seborrheic/diagnosis , Neurilemmoma/therapy , Laser Therapy , Xanthomatosis/therapy
3.
Korean J Intern Med ; 37(5): 931-944, 2022 09.
Article in English | MEDLINE | ID: mdl-35882565

ABSTRACT

Familial hypercholesterolemia (FH) is the most common monogenic disorder. Due to the marked elevation of cardiovascular risk, the early detection, diagnosis, and proper management of this disorder are critical. Herein, the 2022 Korean guidance on this disease is presented. Clinical features include severely elevated low-density lipoprotein cholesterol (LDL-C) levels, tendon xanthomas, and premature coronary artery disease. Clinical diagnostic criteria include clinical findings, family history, or pathogenic mutations in the LDLR, APOB, or PCSK9. Proper suspicion of individuals with typical characteristics is essential for screening. Cascade screening is known to be the most efficient diagnostic approach. Early initiation of lipid-lowering therapy and the control of other risk factors are important. The first-line pharmacological treatment is statins, followed by ezetimibe, and PCSK9 inhibitors as required. The ideal treatment targets are 50% reduction and < 70 or < 55 mg/dL (in the presence of vascular disease) of LDL-C, although less strict targets are frequently used. Homozygous FH is characterized by untreated LDL-C > 500 mg/dL, xanthoma since childhood, and family history. In children, the diagnosis is made with criteria, including items largely similar to those of adults. In women, lipid-lowering agents need to be discontinued before conception.


Subject(s)
Hyperlipoproteinemia Type II , Xanthomatosis , Adult , Child , Cholesterol, LDL , Ezetimibe/therapeutic use , Female , Humans , Hyperlipoproteinemia Type II/diagnosis , Hyperlipoproteinemia Type II/drug therapy , Hyperlipoproteinemia Type II/genetics , Proprotein Convertase 9/genetics , Xanthomatosis/diagnosis , Xanthomatosis/etiology , Xanthomatosis/therapy
6.
Article in English | MEDLINE | ID: mdl-32566950

ABSTRACT

INTRODUCTION: Xanthelasma palpebrarum (XP) is a common xanthomatous lesion of the eyelid and periorbital skin. Several methods of treatment have been reported in the literature, each having its own indications and risks. We present a new treatment method for removing XP using a plasma exeresis device (Plexr®, GMV, Italy). METHODS: Fifteen patients with a total of 27 treated XPs were assessed and clinically identified by the treating dermatologist. Patients were photographed and assessed by a dermatologist prior to and immediately after treatment. A patient survey was conducted 12 months after the procedure, which assessed the outcome of the procedure (redness, pigmentation disorders, and scars). RESULTS: After just a single treatment session using a plasma sublimation, all 27 XPs showed complete clearance. There were no reports of scars, pigmentary alteration, or recurrence of lesions up to 12 months. CONCLUSIONS: We present plasma sublimation as a new method for the treatment of XP. During the procedure, the method allows to control the depth of tissue destruction and the presence of xanthoma tissue, and to minimize pain and trauma, making it particularly ideal for treating areas around the eye.


Subject(s)
Eyelid Diseases/therapy , Laser Therapy , Plasma Skin Regeneration , Xanthomatosis/therapy , Aged , Female , Humans , Male , Middle Aged , Patient Satisfaction , Retrospective Studies , Treatment Outcome
9.
Med Oral Patol Oral Cir Bucal ; 23(4): e429-e435, 2018 Jul 01.
Article in English | MEDLINE | ID: mdl-29924759

ABSTRACT

BACKGROUND: Oral verruciform xanthoma (OVX) is a rare lesion. The purpose of the present study is to describe the clinical features of 13 OVXs and review all cases reported in the English literature. MATERIAL AND METHODS: Thirteen cases of OVX diagnosed during a 47-year period were retrospectively collected. The patients gender and age, as well as the main clinical features of the lesions were retrieved from the biopsy request forms. Pubmed, Scopus and Google ScholarTM electronic databases were searched with the key word verruciform xanthoma. Only cases of histologically confirmed OVX were included in the study. RESULTS: The 13 OVXs represented approximately 0.04% of 35,617 biopsies accessioned during the study period. They affected 13 patients, 8 males and 5 females with a mean age of 48.8±14 years. They mainly appeared as asymptomatic granular nodules or plaques, with elastic or normal consistency and white color, in the gingiva or hard palate. Literature review yielded 416 cases of OVX. With the addition of cases of the present study, 429 cases of OVX have been presented in the English literature. OVX has a slight male predominance with a male to female ratio of 1.4:1 and the majority of patients are in the 5th to 7th decade of life. Clinically, OVX mainly presents as an asymptomatic, single, papillary or granular plaque or nodule, with elastic or soft consistency and white, red or pink color. It measures approximately 1cm and is most commonly located on the gingiva, tongue, hard palate or buccal mucosa. The treatment of choice is surgical excision with little rates of recurrence. CONCLUSIONS: Verruciform xanthoma is a rare lesion most often encountered on the ginigival mucosa. As its clinical presentation is not pathognomonic, it should be included in the differential diagnosis of verrucous or papillary lesions.


Subject(s)
Mouth Diseases , Xanthomatosis , Adult , Aged , Female , Humans , Male , Middle Aged , Mouth Diseases/diagnosis , Mouth Diseases/therapy , Retrospective Studies , Xanthomatosis/diagnosis , Xanthomatosis/therapy
10.
Asia Pac J Ophthalmol (Phila) ; 6(5): 435-443, 2017.
Article in English | MEDLINE | ID: mdl-28829109

ABSTRACT

PURPOSE: Adult xanthogranulomatous disease of the orbit and ocular adnexa is a rare disease that can cause serious morbidity and mortality. Ophthalmologists are commonly the first clinicians to come in contact with affected patients and an understanding of the clinical features is essential. DESIGN: We present a retrospective case series of patients seen in the oculoplastic unit of a large tertiary referral hospital over a 20-year period. METHODS: The clinical files of 7 patients with adult xanthogranulomatous disease of the orbit and ocular adnexa were reviewed. Clinical, radiological, histopathological, and immunohistochemical findings were examined. RESULTS: Periocular clinical features included cutaneous xanthogranulomatous lesions, decreased visual acuity, proptosis, diplopia, skin ulceration, cicatricial ectropion, and mechanical ptosis. Systemic features included adult-onset asthma, disseminated xanthogranulomatous lesions with long bone involvement, and hematological disturbances such as monoclonal gammopathy and lymphoplasmacytic lymphoma. Lipid-laden macrophages and Touton multinucleated giant cells were histological hallmarks in all subtypes. Most lesions were strongly CD8 positive on immunohistochemistry. Radiologically, the lesions were diffuse and infiltrative in nature. Various treatments were employed with varying success including surgical excision, systemic and intralesional corticosteroids, other immunosuppressants, and systemic chemotherapy. CONCLUSIONS: Adult xanthogranulomatous disease of the orbit and ocular adnexa, although rare, may be sight or life threatening. Recognition by the ophthalmologist is critical as periocular features often constitute the initial presentation.


Subject(s)
Eye Diseases , Granuloma , Orbital Diseases , Xanthomatosis , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Anti-Inflammatory Agents/therapeutic use , Blepharoptosis/pathology , Eye Diseases/pathology , Eye Diseases/therapy , Female , Granuloma/pathology , Granuloma/therapy , Humans , Immunohistochemistry , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Orbital Diseases/pathology , Orbital Diseases/therapy , Retrospective Studies , Tomography, X-Ray Computed , Xanthomatosis/pathology , Xanthomatosis/therapy , Young Adult
11.
Skeletal Radiol ; 46(10): 1447-1452, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28660405

ABSTRACT

Xanthogranulomatous osteomyelitis (XO) is an exceedingly rare disease characterized by infiltration of histiocytes and foamy macrophages. Both on gross examination and on radiographs, XO can mimic malignancy. We describe the case of a 5-year-old female with Alagille syndrome who presented with a pathologic fracture of the right humerus. Initial radiographs revealed multiple osteolytic lesions in the distal humerus while MRI showed a large soft tissue mass. Biopsy confirmed the diagnosis of XO, which has hitherto not been described in a patient with Alagille syndrome. The patient was admitted for IV antibiotics and taken to the operating room for an incision and debridement. Tissue cultures were obtained and grew Salmonella. Antibiotic therapy was tapered, and the patient responded to treatment. She was doing well at her 6-month follow-up visit. In the discussion section, we explore how osteopenia and immune dysregulation caused by Alagille syndrome can affect the development of XO. We summarize all previously reported cases of XO and conclude that XO presents as an osteolytic lesion that expands rapidly over the course of a few weeks. We highlight that XO can mimic sarcoma because of its mass effect but can be distinguished radiographically by the presence of surrounding sclerosis. Given the rapid onset of XO, we classify it as an acute osteomyelitis. We discuss how leukemia and Ewing sarcoma can present similarly to acute osteomyelitis. We then emphasize key features that can be used to distinguish these malignancies from acute osteomyelitis.


Subject(s)
Alagille Syndrome/complications , Granuloma/diagnostic imaging , Humeral Fractures/diagnostic imaging , Osteomyelitis/diagnostic imaging , Xanthomatosis/diagnostic imaging , Biopsy , Child, Preschool , Combined Modality Therapy , Diagnosis, Differential , Female , Granuloma/microbiology , Granuloma/therapy , Humans , Humeral Fractures/therapy , Magnetic Resonance Imaging , Osteomyelitis/microbiology , Osteomyelitis/therapy , Xanthomatosis/microbiology , Xanthomatosis/therapy
12.
Brain Pathol ; 27(3): 377-395, 2017 05.
Article in English | MEDLINE | ID: mdl-28236350

ABSTRACT

Xanthomatous lesions of the sellar region have traditionally been divided into two separate categories, xanthomatous hypophysitis (XH) and xanthogranuloma (XG) of the sellar region. The seminal article on XH, a condition typified by foamy histiocytes and lymphoplasmacytic infiltrates in the pituitary gland/sellar region, but usually little or no hemosiderin pigment, detailed three patients. However, most reports since that time have been single cases, making understanding of the entity difficult. In contrast, the seminal report on XG, characterized by sellar region cholesterol clefts, lymphoplasmacytic infiltrates, marked hemosiderin deposits, fibrosis, multinucleated giant cells around cholesterol clefts, eosinophilic granular necrotic debris, and accumulation of macrophages, included 37 patients, allowing more insights into etiology. Few examples could be linked to adamantinomatous craniopharyngioma, and although ciliated epithelium similar to that of Rathke cleft cyst (RCC) was identified up to 35% of the 37 cases, it could not be proven that XG was related to hemorrhage into RCC. Case reports since that time, however, occasionally linked XG to RCC when an etiology could be identified at all, and a few recognized that a spectrum exists in xanthomatous lesions of the sella. They review literature, adding 23 cases from our own experience, to confirm that overlap occurs between XH and XG, and that the majority-but not all-can be linked to RCC leakage/rupture/hemorrhage. It was suggested that progressive accumulation of hemosiderin pigment in the lesion, possibly caused by the multiple episodes of bleeding, could account for the transition of at least some cases of XH to XG.


Subject(s)
Pituitary Diseases/epidemiology , Pituitary Diseases/pathology , Sella Turcica , Xanthomatosis/epidemiology , Xanthomatosis/pathology , Adolescent , Adult , Aged , Brain/diagnostic imaging , Child , Child, Preschool , Cohort Studies , Female , Granuloma/diagnostic imaging , Granuloma/epidemiology , Granuloma/pathology , Granuloma/therapy , Humans , Hypophysitis , Male , Middle Aged , Pituitary Diseases/diagnostic imaging , Pituitary Diseases/therapy , Xanthomatosis/diagnostic imaging , Xanthomatosis/therapy , Young Adult
13.
J Gastrointestin Liver Dis ; 25(3): 389-94, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27689205

ABSTRACT

Gastrointestinal xanthomas are infrequent non-neoplastic lesions characterized by the accumulation of foam cells in the lamina propria. They are commonly seen in association with dyslipidemia, chemotherapy or radiotherapy, and infections in immunosuppressed patients. However, no clear connection to hyperlipidemia has been found. They occur more frequently in the stomach, and are very rare in the small bowel and esophagus. We identified all cases of non-gastric xanthoma or xanthomatosis reported in the English literature by searching the PubMed database and retrospectively reviewed the clinical, endoscopic, and histopathologic features of the 11 cases of non-gastric gastrointestinal xanthomas diagnosed in our hospital. Nine lesions were located in the large bowel, one in the duodenum and one in the esophagus. All xanthomas were small (<5 mm) sessile polyps except the esophageal xanthoma, which measured 13 mm. Two cases in the large bowel and the case in the small bowel were multiple. Most patients with large bowel xanthomas had hypercholesterolemia, unlike esophageal and small bowel cases. The esophageal lesion occurred in a patient with a history of partial fundoplication due to gastroesophageal reflux disease and the small bowel case was associated to chronic atrophic gastritis with intense activity. In our search of the English literature, we found 19 cases of xanthoma or xanthomatosis in the esophagus, 13 cases in the small bowel and 61 cases in the large bowel. In conclusion, gastrointestinal xanthomas, other than the gastric ones, are rare, and are usually incidental findings.


Subject(s)
Esophageal Diseases , Intestinal Diseases , Xanthomatosis , Adult , Aged , Aged, 80 and over , Biopsy , Child, Preschool , Esophageal Diseases/diagnosis , Esophageal Diseases/etiology , Esophageal Diseases/therapy , Female , Humans , Incidental Findings , Intestinal Diseases/diagnosis , Intestinal Diseases/etiology , Intestinal Diseases/therapy , Male , Middle Aged , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk Factors , Xanthomatosis/diagnosis , Xanthomatosis/etiology , Xanthomatosis/therapy , Young Adult
14.
Graefes Arch Clin Exp Ophthalmol ; 254(3): 413-20, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26794218

ABSTRACT

PURPOSE: Adult-onset xanthogranuloma (AOX) of the corneoscleral limbus is a rare inflammatory condition of unknown aetiology. Similar to limbal juvenile xanthogranuloma (JXG), it presents as a growing mass at the corneoscleral junction. Limbal AOX and JXG can lead to sight-threatening complications if not managed in a timely manner. This systematic review summarises the main clinical and histopathological features of limbal AOX/JXG and discusses the management of this uncommon disease. METHODS: We performed a literature search in the MEDLINE database for all historical entries, using the search terms "limbus", "limbal" and "xanthogranuloma", and retrieved all articles reporting on limbal xanthogranuloma. After refining the search to articles relevant to limbal AOX, we were able to identify ten adult cases of limbal AOX and compare those with all reported cases of limbal JXG. RESULTS: Clinically, AOX usually presents as an isolated smooth, yellowish, dome-shaped nodule at the corneoscleral junction, similar to an ocular presentation of JXG, with which it also shares similar histopathological features. CONCLUSION: Limbal JXG and AOX may represent the same disease entity. Diagnosis relies on the clinical presentation, pathology and immunohistochemical profile. Spontaneous regression is unlikely, and thus prompt surgical intervention should be considered to prevent sight-threatening complications. Xanthogranuloma should be included in the differential diagnosis of corneoscleral limbal masses in patients of all age groups.


Subject(s)
Corneal Diseases , Granuloma , Limbus Corneae , Xanthogranuloma, Juvenile , Xanthomatosis , Adolescent , Adult , Aged , Child, Preschool , Corneal Diseases/diagnosis , Corneal Diseases/epidemiology , Corneal Diseases/therapy , Female , Granuloma/diagnosis , Granuloma/epidemiology , Granuloma/therapy , Humans , Male , Middle Aged , Xanthogranuloma, Juvenile/diagnosis , Xanthogranuloma, Juvenile/epidemiology , Xanthogranuloma, Juvenile/therapy , Xanthomatosis/diagnosis , Xanthomatosis/epidemiology , Xanthomatosis/therapy , Young Adult
15.
Blood Purif ; 41(4): 264-9, 2016.
Article in English | MEDLINE | ID: mdl-26731699

ABSTRACT

Homozygous familial hypercholesterolemia (HoFH) is a very rare condition (1 case per 1 million people) with a dismal outcome due to inevitable coronary artery disease that occurs when left untreated. Lipoprotein apheresis (LA), previously known as low-density lipoprotein (LDL) apheresis, is very effective in reducing LDL-cholesterol (LDL-C) if HoFH is refractory to aggressive drug therapy and diet control. In this study, we report a case with HoFH, who presented with xanthomata over the 4 limbs when she was 3 years old. When she was 11 years old, she began treatment with semi-selective LA with double filtration plasmapheresis (DFPP) once per week because HoFH was refractory to high-dose statin and diet control. LDL-C was reduced from 8.2 ± 0.9 to 2.69 ± 0.75 mmol/l (reduction rate = 67.3 ± 6.1%). The xanthomata over the 4 limbs were nearly completely resolved after 2 years of DFPP. Two years later, after the initiation of DFPP, we performed coronary angiography and echocardiography for regular checkup in the absence of chest pain, and the result was negative. To date (11 years after initiation of DFPP), she has not complained of any chest pain, shown intolerance to exercise, or exhibited ST-T change on electrocardiography. At the age of 20, multidetector computed tomography showed no significant stenosis over the coronary arteries. At the most recent follow-up visit, she was found to have good heart function and no xanthomata. LA is effective in the treatment of HoFH when drug therapy and diet control fail. With this treatment, pre-existing xanthomata can regress and coronary artery disease can be prevented.


Subject(s)
Hyperlipoproteinemia Type II/therapy , Plasmapheresis/methods , Xanthomatosis/therapy , Cholesterol, LDL/blood , Coronary Angiography , Coronary Artery Disease/prevention & control , Female , Homozygote , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/complications , Hyperlipoproteinemia Type II/diagnostic imaging , Rosuvastatin Calcium/therapeutic use , Time Factors , Treatment Outcome , Xanthomatosis/blood , Xanthomatosis/complications , Xanthomatosis/diagnostic imaging , Young Adult
16.
Arch Pediatr ; 23(12): 1247-1250, 2016 Dec.
Article in English | MEDLINE | ID: mdl-28492167

ABSTRACT

Alagille syndrome causes intractable pruritus and disfiguring xanthomas because of retained bile acids and cholesterol. Drug therapy in addition to surgical intervention may be effective in many patients in reducing serum bile acids, cholesterol levels, pruritus, and skin xanthomas. In this report, we describe a child with Alagille syndrome who presented with severe pruritus and xanthomas as a consequence of severe hypercholesterolemia and discuss the treatment modalities.


Subject(s)
Alagille Syndrome/complications , Cholestasis/etiology , Pruritus/etiology , Xanthomatosis/etiology , Child , Cholestasis/therapy , Humans , Hypercholesterolemia/complications , Hypercholesterolemia/genetics , Male , Pruritus/therapy , Xanthomatosis/therapy
19.
Cornea ; 34(12): 1620-2, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26509771

ABSTRACT

PURPOSE: To report a rare case of atypical fibroxanthoma (AFX) of the bulbar conjunctiva, and to compare it with previously published cases of conjunctival AFX. METHODS: A 37-year-old woman developed a growth on the bulbar conjunctiva of her left eye that increased in size and redness over 4 months and was associated with blurry vision in the left eye, occasional diplopia, irritation of the eye, and increasing tearing. The mass was surgically excised. RESULTS: Slit-lamp examination disclosed a highly vascularized conjunctival lesion with intact lustrous epithelium and a raised nodular edge encroaching on the nasal corneal limbus of the left eye. Pathological examination and immunohistochemistry were diagnostic of AFX. CONCLUSIONS: AFX of the conjunctiva is rare, with this being only the fifth example of this neoplasm reported at this site. Complete surgical excision is the most appropriate treatment option.


Subject(s)
Conjunctival Diseases/pathology , Xanthomatosis/pathology , Adult , Alkylating Agents/administration & dosage , Combined Modality Therapy , Conjunctival Diseases/therapy , Cryotherapy , Female , Humans , Limbus Corneae/pathology , Mitomycin/administration & dosage , Sclera/drug effects , Tenon Capsule/drug effects , Xanthomatosis/therapy
20.
Anticancer Res ; 35(11): 5717-35, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26503993

ABSTRACT

BACKGROUND: Atypical fibroxanthoma (AFX) is an uncommon, rapidly growing cutaneous neoplasm of uncertain histogenesis. Thus far, there are no guidelines for diagnosis and therapy of this tumor. PATIENTS AND METHODS: We included 18 patients with 21 AFX, and 2,912 patients with a total of 2,939 AFX cited in the literature between 1962 and 2014. RESULTS: In our cohort, excision with safety margin was performed in 100% of primary tumors. Local recurrences were observed in 25% of primary tumors and parotid metastases in 5%. Ten-year disease-specific survival was 100%. The literature research yielded 280 relevant publications. Over 90% of the reported cases were negative for cytokeratins, S100, desmin and human melanoma black 45 (HMB-45). Recurrent AFX was reported in 7.6% and metastasizing AFX in 2.75% cases. No significant differences in the recurrence and survival rates following wide local excision versus Mohs microsurgery were observed. Twenty-year disease-specific survival rate was 97.8%. CONCLUSION: A well-selected panel of immunohistochemical markers is necessary to establish AFX diagnosis with sufficient certainty. Adequately treated, AFX has an excellent prognosis, but long-term follow-up is recommended due to the potential for aggressive behavior.


Subject(s)
Biomarkers, Tumor/metabolism , Fibroma/diagnosis , Histiocytoma, Benign Fibrous/diagnosis , Skin Neoplasms/diagnosis , Xanthomatosis/diagnosis , Fibroma/metabolism , Fibroma/therapy , Histiocytoma, Benign Fibrous/metabolism , Histiocytoma, Benign Fibrous/therapy , Humans , Prognosis , Skin Neoplasms/metabolism , Skin Neoplasms/therapy , Xanthomatosis/metabolism , Xanthomatosis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL